title: Retroperitoneal in-line aortic bypass for treatment of infected infrarenal aortic grafts.
abstract: Since 1970, we have treated 43 patients with infected aortic grafts. Early in the series, four patients were treated with resection of the fistula or erosion and systemic and topical antibiotics without removal of the graft. All four patients died. Thirty-two patients were treated by conventional therapy; there were 13 deaths (40 percent). More recently, seven patients were managed by the left retroperitoneal placement of a new in-line polytetrafluoroethylene (PTFE) aortic graft through clean tissue planes, followed by the immediate transperitoneal removal of the infected graft without cross-contamination. Patients were maintained postoperatively on antibiotics for a minimum of two weeks. All seven patients survived without septic complications, with a mean follow-up time of 36 months (six months to four years). The surgical technique consists of initial suprarenal control of the aorta, followed by infrarenal division and oversewing of the distal aorta. A PTFE bifurcation graft is placed connecting the proximal aorta and the appropriate femoral vessels, the right limb tunneled through the space of Retzius. After closure of the incisions, through the space of Retzius. After closure of the incisions, the patient is placed in the supine position and the infected graft is removed transperitoneally. We believe that retroperitoneal in-line aortic bypass for treatment of an infected aortic graft offers a favorable alternative to conventional therapy by avoiding the use of an extra-anatomic bypass and associated risk of stump blowout.
authors.affiliation: Vascular Surgery Section, Albany Medical College, New York 12208.
authors.forename: R P
authors.initials: RP
authors.lastname: Leather
authors.forename: R C
authors.initials: RC
authors.lastname: Darling
authors.forename: B B
authors.initials: BB
authors.lastname: Chang
authors.forename: D M
authors.initials: DM
authors.lastname: Shah
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001018:Aortic Diseases / Q000601:surgery*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects* / Q000592:standards; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D017052:Hospital Mortality; D006785:Hospitals, University; D006801:Humans; D009518:New York / Q000453:epidemiology; D011138:Polytetrafluoroethylene / Q000627:therapeutic use*; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D012086:Reoperation / Q000379:methods* / Q000592:standards; D015996:Survival Rate
chemical_list: D000900:Anti-Bacterial Agents; D011138:Polytetrafluoroethylene